Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | CA4 | P22748 | 1/20 | 0.46 |
| ▸ | CA7 | P43166 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | IAPP | P10997 | 3/20 | 0.37 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.34 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.34 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.32 |
| ▸ | CETP | P11597 | 1/20 | 0.32 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.32 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.32 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.31 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3110101 | 0.85 | CA12 (0.51) | CA12CA1CA2CA4CA7 | |
| SCHEMBL10585673 | 0.81 | CA12 (0.50) | CA12CA1CA2CA4CA7 | |
| SCHEMBL5880381 | 0.78 | CYP4F2 (0.61) | CA12CA1CA2CA4CA7 | |
| SCHEMBL12419024 | 0.78 | CA12 (0.55) | CA12CA1CA2CA4CA7 | |
| SCHEMBL7442231 | 0.77 | LMNA (0.37) | ALDH1A1LMNAIAPPCYP4F2CYP4A11 | |
| SCHEMBL4601863 | 0.74 | CYP4F2 (0.47) | ALDH1A1LMNAIAPPCYP4F2CYP4A11 | |
| SCHEMBL4601007 | 0.73 | TAAR1 (0.50) | ALDH1A1CYP4F2CYP4A11 | |
| SCHEMBL7346534 | 0.72 | POLB (0.38) | CA12CA1CA2CA4CA7 | |
| SCHEMBL7346532 | 0.71 | EPHX2 (0.40) | CA12CA1CA2CA4CA7 | |
| SCHEMBL171971 | 0.71 | CA12 (0.47) | CA12CA1CA2CA4CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6486315-B2 | RECRYSTALLIZING MERCAPTOALKANOYLAMINO LACTAM ACID UNDER BASIC CONDITIONS USING AN AGENT THAT MINIMIZES AMOUNT OF DISULFIDES | BRISTOL-MYERS SQUIBB CO. | 2002-11-26 | — | — | US | disclosed |
| US-6444810-B1 | ACYLMERCAPTOALKANOYLAMINO LACTAM ESTERS OR ACIDS ARE CONVERTED TO THE CORRESPONDING MERCAPTOALKANOYLAMINO LACTAM ESTER OR ACID UNDER BASIC CONDITIONS USING AN AGENT THAT MINIMIZES AMOUNT OF DISULFIDES | BRISTOL-MYERS SQUIBB CO. | 2002-09-03 | — | — | US | disclosed |
| EP-1051419-A4 | DEPROTECTION AND RECRYSTALLIZATION PROCESSES | BRISTOL MYERS SQUIBB CO (US) | 2002-08-28 | — | — | EP | disclosed |
| US-20020086995-A1 | Recrystallization processes | KRONENTHAL DAVID R (US) | 2002-07-04 | — | — | US | disclosed |
| US-20020086994-A1 | Acylmercaptoalkanoylamino lactam esters or acids are converted to the corresponding mercaptoalkanoylamino lactam ester or acid under basic conditions using an agent that minimizes amount of disulfides | KRONENTHAL DAVID R (US) | 2002-07-04 | — | — | US | disclosed |
| US-6340752-B1 | CLEAVAGE OF THIO GROUP FROM CARBONYL AND CONVERSION TO LACTAM ESTER | BRISTOL-MYERS SQUIBB CO. | 2002-01-22 | — | — | US | disclosed |
| EP-1051419-A1 | DEPROTECTION AND RECRYSTALLIZATION PROCESSES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2000-11-15 | — | — | EP | disclosed |
| WO-1999035145-A1 | DEPROTECTION AND RECRYSTALLIZATION PROCESSES | BRISTOL-MYERS SQUIBB COMPANY (US) | 1999-07-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020086994-A1 | Acylmercaptoalkanoylamino lactam esters or acids are converted to the corresponding mercaptoalkanoylamino lactam ester or acid under basic conditions using an agent that minimizes amount of disulfides | MPST, PTMS, TST | CA12 357/4885CA1 491/4885CA2 1024/4885 |
| US-20020086995-A1 | Recrystallization processes | MPST, TST, SLC39A11 | CA12 896/4885CA1 1207/4885CA2 1740/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.